MICRO-X LIMITED (MX1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MX1 - MICRO-X LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.32
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.13

03 Oct
2023

0.000

OPEN

$0.13

0.000

HIGH

$0.13

389,427

LOW

$0.13

TARGET
$0.27 107.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MEB . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
MX1: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 2.2 - 0.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-2.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx15.0 M
Book Value Per Share xxxxxxxxxxxxxxx3.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.0 M
Net Profit Margin xxxxxxxxxxxxxxx-71.67 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-59.17 %
Return on Invested Capital xxxxxxxxxxxxxxx-47.65 %
Return on Assets xxxxxxxxxxxxxxx-34.93 %
Return on Equity xxxxxxxxxxxxxxx-59.17 %
Return on Total Capital xxxxxxxxxxxxxxx-70.10 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx3.60

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.8 M
Capex % of Sales xxxxxxxxxxxxxxx5.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx22 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

31/08/2023

1

Speculative Buy

$0.27

107.69%

Micro-X's FY23 results were just slightly in advance of Morgans forecasts with a net loss of -$10.7m compared to the expected -$11.9m.

At June 30, the company had $5.2m cash and management expects to improve its near-term cash position after receiving its FY23 R&D tax incentive refund this quarter, and after converting around $6m of inventory to cash.

The analysts highlight the key upcoming near-term catalyst is the commercial launch of Argus.

The target eases to 27c from 28c and the Speculative Buy rating is unchanged.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.80 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.30 cents.
Access Stockbroker Research History >

MX1 STOCK CHART

FNArena News on MX1

1
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
2
FNArena Corporate Results Monitor – 31-08-2023

Aug 31 2023 - Australia
3
FNArena Corporate Results Monitor – 28-02-2023

Feb 28 2023 - Australia
4
FNArena Corporate Results Monitor – 31-08-2022

Aug 31 2022 - Australia
5
Rudi’s View: Adairs, Gentrack, ReadyTech, Macquarie, Qantas And Nufarm

Oct 21 2021 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
2
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
3
ResMed: Finding A Base?

Aug 15 2023 - Technicals
4
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
5
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
6
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
7
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
8
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest
9
Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023 - Small Caps
10
Dr Boreham’s Crucible: SDI

Mar 16 2023 - Small Caps